What is Cronos Group Inc (CRON) stock price today?

Cronos Group Inc (CRON) currently trades at $2.58 per share. The stock has a market capitalization of $1.02B and a P/E ratio of —x.

Is CRON stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Cronos Group Inc has a Smart Value Score of 44/100 (Grade D), resulting in a "Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is 13.63.

What is Cronos Group Inc's revenue and earnings?

Cronos Group Inc has trailing twelve-month (TTM) revenue of $146.59M with profit margins of -6.45%. Earnings per share (EPS) is $-0.02.

Is Cronos Group Inc financially healthy?

Cronos Group Inc's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of 13.63 places it in the safe zone.

CRON

Cronos Group Inc

NASDAQ: CRON · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$2.58

-2.64% today

Updated 2026-04-29

Market cap

$1.02B

P/E ratio

—

P/S ratio

6.93x

EPS (TTM)

$-0.02

Dividend yield

—

52W range

$2 – $3

Volume

1.5M

Market cap

$1.02B

P/E ratio

—

P/S ratio

6.93x

EPS (TTM)

$-0.02

Dividend yield

—

52W range

$2 – $3

Volume

1.5M

WallStSmart proprietary scores

out of 100

Grade: D

Sell

Investment rating

10.0

Growth

A+

8.5

Quality

2.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

13.6

Altman Z-Score

Safe zone

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$2.30

-10.74%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy3 Buy1 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Altman Z 13.63 — safe zone

+ Free cash flow $9.87M — positive

+ Revenue growth 47.00% QoQ

+ Debt/equity 0.00x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Thin margins at -6.45%

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$86.75M	$87.24M	$117.61M	$193.36M	$146.59M
Net income	$-168.73M	$-73.96M	$41.08M	$-9.45M	$-1.82M
EPS	—	—	—	—	$-0.02
Free cash flow	$-93.98M	$-46.26M	$5.69M	$151611.00	$9.87M
Profit margin	-194.51%	-84.78%	34.93%	-4.89%	-6.45%

Recent insider activity

Date	Insider	Type	Shares	Price
2026-03-19	SHLIMAK, ANNA	Sale	28,429	—
2026-03-19	SHLIMAK, ANNA	Buy	28,429	—
2026-03-19	SHLIMAK, ANNA	Sale	9,767	$2.54

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
CRON	$1.02B	44	10.0	2.0	5.0	8.5	—	Hold
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Cronos Group Inc trades at $2.58. Our Smart Value Score of 44/100 indicates the stock is fair. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 13.63, it sits in the safe zone. TTM revenue stands at $146.59M. with profit margins at -6.45%.

Frequently asked questions

What is Cronos Group Inc's stock price?

Cronos Group Inc (CRON) trades at $2.58.

Is Cronos Group Inc overvalued?

Smart Value Score 44/100 (Grade D, Sell).

What is the price target of Cronos Group Inc (CRON)?

The analyst target price is $2.30, representing -10.7% downside from the current price of $2.58.

What is Cronos Group Inc's revenue?

TTM revenue is $146.59M.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

13.63 — safe zone.

Company info

SectorHEALTHCARE

IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC

CountryUSA

ExchangeNASDAQ

CurrencyUSD

thecronosgroup.com

Quick metrics

P/S ratio6.93x

ROE-0.26%

Beta1.21

50D MA$2.60

200D MA$2.54

Shares out0.38B

Float0.20B

Short ratio—

Avg volume1.5M

Performance

1 week+3.88%

1 month+8.94%

3 months+5.93%

YTD+1.90%

1 year—

3 years—

5 years—

Compare

CRON vs LLY →CRON vs JNJ →CRON vs ABBV →Stock screener →